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Abstract
Background The efficacy, safety and immunogenicity risk
of switching between an originator biologic and a
biosimilar or from one biosimilar to another are of potential
concern.
Objectives The aim was to conduct a systematic literature
review of the outcomes of switching between biologics and
their biosimilars and identify any evidence gaps.
Methods A systematic literature search was conducted in
PubMed, EMBASE and Cochrane Library from inception
to June 2017. Relevant societal meetings were also
checked. Peer-reviewed studies reporting efficacy and/or
safety data on switching between originator and biosimilar
products or from one biosimilar to another were selected.
Studies with fewer than 20 switched patients were exclu-
ded. Data were extracted on interventions, study popula-
tion, reason for treatment switching, efficacy outcomes,
safety and anti-drug antibodies.
Results The systematic literature search identified 63 pri-
mary publications covering 57 switching studies. The
reason for switching was reported as non-medical in 50
studies (23 clinical, 27 observational). Seven studies (all
observational) did not report whether the reasons for
switching were medical or non-medical. In 38 of the 57
studies, fewer than 100 patients were switched. Follow-up
after switching went beyond 1 year in eight of the 57
studies. Of the 57 studies, 33 included statistical analysis of
disease activity or patient outcomes; the majority of these
studies found no statistically significant differences
between groups for main efficacy parameters (based on
P\0.05 or predefined acceptance ranges), although some
studies observed changes for some parameters. Most
studies reported similar safety profiles between groups.
Conclusions There are important evidence gaps around
the safety of switching between biologics and their
biosimilars. Sufficiently powered and appropriately statis-
tically analysed clinical trials and pharmacovigilance
studies, with long-term follow-ups and multiple switches,
are needed to support decision-making around biosimilar
switching.
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article (https://doi.org/10.1007/s40259-017-0256-z) contains supple-
mentary material, which is available to authorized users.
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We believe that sufficiently powered and
appropriately statistically analysed trials and
pharmacovigilance studies, with long-term follow-
ups and multiple switching sequences, are still
needed to support decision-making around biosimilar
interchangeability.
In the interim, switching should remain a clinical
decision made by the treating physician and the
patient based on available evidence and individual
patient circumstances.
1 Introduction
Biological medicines (‘biologics’) are derived from living
organisms, often by using recombinant DNA technology.
Biologics differ from traditional, small molecule medici-
nes, which are generally structurally simple, chemically
synthesised and easily characterised analytically. Post-
translational modifications of biologics are particularly
vulnerable to manufacturing process conditions, and
maintaining batch-to-batch consistency is essential [1].
Small process changes (‘evolution’) or unintentional
deviations (‘drift’) can lead to changes in the biological end
product and, ultimately, to product divergence, a concept
that has particular relevance in the setting of biosimilars
[2].
Quality assessment of biologics in terms of efficacy and
safety requires physicochemical and functional assays,
pharmacokinetic and pharmacodynamic evaluations, toxi-
city testing in animals and clinical pharmacology [3–5].
Unwanted immune responses are a concern, both in terms
of adverse events (e.g. anaphylaxis, infusion reactions) and
neutralisation of either the therapeutic biologic or the
endogenous counterparts by neutralising antibodies, and
have terminated development of some biologics [6].
Biosimilars have established similarity to the biologic
reference product in terms of safety and efficacy. There are
stringent regulatory requirements for demonstration of
biosimilarity—including demonstration of comparable
physicochemical characteristics, biological activity, effi-
cacy and safety/immunogenicity—and these are laid down
in the respective US Food and Drug Administration (FDA)
and European Union (EU) guidance documents, and the
approval process of biosimilars in these highly regulated
markets is rigorous [4, 5, 7–10]. However, unlike generics
of small molecule medicines (which can be fully charac-
terised structurally, thus allowing for the same drug sub-
stance to be produced), biosimilars of biologic reference
products can differ in terms of the overall structure of their
drug substance and are similar to, but not identical to, the
originator product. This is because biologics are large and
structurally complex, meaning that, unlike the characteri-
sation of generics, current analytical methodology may not
be able to detect or characterise all relevant structural and
functional differences between biologics, a distinction that
is also noted in the FDA guidance on demonstrating
biosimilarity and the Australian Therapeutic Goods
Administration (TGA) biologic nomenclature consultation
[3, 11]. Data on the efficacy and safety of initiating therapy
with a biosimilar versus with an originator biologic, gen-
erated as part of regulatory approval and post-approval
phases, have been widely reviewed [12–14] and are not the
focus of the current article.
‘Interchangeability’ is the medical practice of changing
one medicine for another that is expected to achieve the
same clinical effect in a given clinical setting and in any
patient, on the initiative, or with the agreement, of the
prescriber [15, 16]. ‘Switching’ refers to the treating
physician exchanging one medicine with another medicine
with the same therapeutic intent in a given patient [17].
Substitution is the practice of dispensing one medicine
instead of another equivalent and interchangeable medicine
at the pharmacy level without consulting the prescriber
[15]. Implied in this is that a biosimilar has been shown to
produce the same result as the originator in any patient and
that there are no signals suggesting loss of efficacy or
increased toxicity if multiple switches are made in the
cases in which the medicine must be administered on many
occasions.
Definitions of biosimilarity and interchangeability used
in the USA, the EU and Australia are summarised in
Supplementary Table 1 (see the electronic supplementary
material) [4, 5, 7–10]. For a reference product and a
biosimilar to be considered interchangeable, the FDA
requires sponsors to demonstrate that the risk in terms of
side effects or diminished efficacy of switching is not
greater than the risk of using the reference product without
such alternating or switching [18]. Recently published
FDA draft guidance on the specific data required to achieve
a designation of interchangeability states that for products
that are administered more than once, marketing applica-
tions are expected to include data from switching studies in
appropriate conditions of use [19]. In the EU, substitution
policies are within the remit of each member state [4].
However, officials from Finnish, Dutch, German and
Norwegian national regulatory agencies concluded in a
recent ‘current opinion’ article, published in BioDrugs, that
‘‘biosimilars licensed in the EU are interchangeable’’ [17].




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Review of Biosimilarity and Interchangeability of Biologics 33
In Australia, the TGA has responsibility for marketing
authorisation (focusing on safety, efficacy and quality),
with the Pharmaceutical Benefit Advisory Committee
(PBAC) advising the government about whether a drug
should be subsidised (focusing on cost-benefit) [20]. The
PBAC has proposed that biosimilar substitution at the
pharmacy level is acceptable when there is ‘‘absence of
data to suggest significant differences in clinical effec-
tiveness or safety compared with the originator product’’
that argue against such action [8]. The interchangeability of
an originator biologic and a biosimilar or between
biosimilars is considered by the PBAC on a case-by-case
basis [8].
Switching between an originator biologic and a
biosimilar medicine or between biosimilars can be cate-
gorised as either medical or non-medical. Medical switch-
ing is initiated by the prescriber because of medical
concerns such as adverse events, or convenience of dosing
or administration. For example, the incidence of injection
site reactions in phase 3 clinical trials was lower with
biosimilar than originator tumour necrosis factor (TNF)
inhibitors, a difference that was explained by a lack of
L-arginine in the formulation and of latex in the needle
shield of the biosimilar products [21]. Non-medical
switching occurs because of non-medical concerns,
including treatment cost or availability. Recommendations
from professional societies around switching are sum-
marised in Supplementary Table 2 [22–37]. Importantly,
across the USA, Canada, Europe and Australia, profes-
sional societies state that the decision to switch has to be
taken by the treating physician. In the USA, for example,
the American Academy of Dermatology (AAD) and the
American College of Rheumatology (ACR) support
switching only if it is deemed suitable by the prescribing
provider [22, 26], and the Australian Rheumatology
Association (ARA) position is that the decision to prescribe
any medication should rest with the prescriber, in consul-
tation with an informed patient, and substitution should not
occur without the knowledge and consent of the patient
[35]. The Australian Diabetes Society and Australian Dia-
betes Educators Association (in a collective statement with
Diabetes Australia), the Gastroenterological Society of
Australia and the Australian Inflammatory Bowel Disease
Association strongly oppose recommendations of biosimi-
lars as interchangeable on the grounds of patient safety
[23, 33]. This is in stark contrast with the Pharmaceutical
Society of Australia and the Pharmacy Guild of Australia,
who support substitution by the pharmacist if the patient
agrees and if the prescribing physician has not specifically
indicated that no substitution should occur [38, 39].
Ongoing areas of scientific debate and potential concern
around biosimilars are (1) extrapolation of approval of


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Review of Biosimilarity and Interchangeability of Biologics 39
of impurities or chemical alterations not detected with stan-
dard comparability testing [40–42], and (3) whether the effi-
cacy, safety and immunogenicity risk of therapy are affected
when patients are switched between originator and biosimilar
products or from one biosimilar to another, in particular when
multiple switching occurs. This article will focus on the third
point, namely the key principles around biosimilarity and
interchangeability, and analyse the available evidence around
switching between originator biologics and biosimilars or
between biosimilars based on a systematic review of the
published literature, identifying any significant evidencegaps.
2 Methods
2.1 Systematic Literature Searches
A systematic literature review was conducted in PubMed,
EMBASE and Cochrane Library to 10 June 2017 to identify
studies reporting efficacy and/or safety data on switching
between originator biologics and biosimilars or between
biosimilars, using the following search string: ((biosimilars
OR biosimilar OR biosimilarity OR ‘‘subsequent entry bio-
logic’’ OR ‘‘subsequent entry biologics’’ OR ‘‘similar bio-
therapeutic product’’ OR ‘‘similar biotherapeutic products’’
OR ‘‘similar biological medicinal product’’ OR ‘‘similar
biological medicinal products’’ OR ‘‘follow-on biologic’’
OR ‘‘follow-on biologics’’) AND (equivalent OR equiva-
lence OR comparability OR substitute OR substitution OR
substitutability OR switch OR switched OR switching OR
interchange OR interchanged OR interchangeable OR
interchangeability)). Records in PubMed were retrieved
using the title and abstract (‘tiab’) search filter. Records in
EMBASE were retrieved using the ‘ex/mj’ syntax to capture
synonyms and apply major focus for all terms.
The following meetings from the main societies represent-
ing key therapeutic areas for biosimilars were checked for
relevant abstracts published in 2015 or 2016: American Asso-
ciation of Clinical Endocrinologists (AACE); AAD; ACR;
American Diabetes Association; American Gastroenterology
Association; American Society of Clinical Oncology (ASCO);
American Society of Nephrology; European Crohn’s and
Colitis Organisation; European Renal Association/European
Dialysis and Transplant Association European Society for
Medical Oncology; and European League against Rheuma-
tism. In addition,ASCOwas also checked for relevant abstracts
published in 2017.
The reference lists of identified primary articles and
literature reviews were hand searched for any additional,
potentially relevant articles. To supplement the systematic
searches, an exploratory literature search was undertaken to
support the overview section around the principles of
biologics, biosimilarity and interchangeability.
2.2 Study Eligibility and Data Extraction
Studies were excluded if they presented data on switching
only between different classes of originator biologics and
biosimilars or between different classes of biosimilars.
Pharmacokinetic/pharmacodynamic cross-over studies in
healthy volunteers were included if more than one dose of
study drug was administered and if data were reported
separately for the post-washout/post-switch study period.
Studies comprising fewer than 20 switch patients were
excluded. No exclusion criteria were applied regarding
study type (clinical or observational), retrospective or
prospective analysis or publication date.
Data were extracted on treatment, indication, study
design, comparators, patient numbers and demographics
(age, sex), reason for treatment switching, efficacy, safety
and anti-drug antibodies (ADAs).
All data were tabulated separately by study type (clini-
cal or observational) and reason for switching (medical or
non-medical). No meta-analyses were performed given the
heterogeneity of study designs, interventions, populations
and methods of analysis.
2.3 Role of Funding Source
The funding source had no role in the conduct of the pre-
sent study.
3 Results
The systematic literature search identified 63 primary
publications, covering 57 switching studies that reported
efficacy and/or safety data [43–105]. A flow chart of the
systematic searches is shown in Figure 1. Forty-one of the
identified studies were reported as full articles; the
remaining 16 studies were covered only in abstract form.
In terms of design, 23 were clinical studies [22 randomised
controlled trials (RCTs), including 11 open-label exten-
sions of RCTs; and one non-RCT cross-over study] and 34
were observational (24 prospective, 10 retrospective).
Patient demographics and other study characteristics are
summarised in Supplementary Table 3 [43–105]. The
number of included patients per study ranged from 20 to
802, except for a retrospective chart review with N = 3018
[72] and an insurance database study with N = 6177 [76].
The average age, where reported, ranged from younger
than 10 years to 71 years, and the proportion of men,
where reported, ranged from 0% to 87%.
The reason for switching was reported as non-medical in
50 studies, of which 23 were clinical studies (Table 1) and
27 were observational studies (Table 2). The remaining
seven studies did not report whether the reasons for
40 R. A. McKinnon et al.
switching were medical or non-medical; all were obser-
vational (Table 3). None of the studies reported having
only medical reasons for switching.
3.1 Non-medical Switching: Clinical Efficacy
and Safety Data
Of the 23 clinical, non-medical switching studies (Table 1)
[53, 55, 56, 60, 61, 69, 70, 73–75, 81, 82, 84–86, 91–99,
101–104], 22 reported data on main efficacy parameters in
switched versus non-switched or pre-switch versus post-
switch groups. The originator biologics/biosimilars asses-
sed were infliximab (six studies [53, 55, 56,
61, 69, 70, 73]), erythropoietin-stimulating agents (ESAs)
(four studies [74, 75, 81, 82]), filgrastim [93–95] (three
studies), insulin [84–86], adalimumab [96–98], rituximab
[60, 99] and etanercept [101–103] (two studies each), and










Publications excluded based on 
manual review of title, abstract 
and/or full text (n=1053)
n = 45
Publications included based 












(n = 63 publications)
23 clinical studies
• 22 RCTs (including 11
  open-label RCT extensions)




Fig. 1 Flow chart of systematic
literature searches. RCT
randomised controlled trial
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































42 R. A. McKinnon et al.
Of these, 15 included statistical analyses of disease
activity or patient outcomes in switched versus non-swit-
ched groups, pre-switch versus post-switch groups or
observed versus predicted outcomes [53, 60, 61, 73,
74, 81, 82, 84–86, 91–95, 99], with five studies specifying a
formal equivalence or non-inferiority margin
[53, 74, 81, 82, 95]. There were no statistically significant
differences between groups (based on P\0.05 or prede-
fined acceptance ranges), with the exception of a significant
weight gain that was observed in patients with type 1
diabetes mellitus switched to biosimilar compared with
patients remaining on originator insulin (? 1.0 kg vs
? 0.2 kg, respectively; P\0.05) in the open-label exten-
sion of the ELEMENT 1 RCT, although the range of
weight changes was wide in both groups [84]. The NOR-
SWITCH infliximab trial was conducted across six indi-
cations and used a non-inferiority margin of 15% (adapted
from rheumatoid arthritis studies), with results suggesting
no loss of efficacy and no unexpected treatment-emergent
adverse events (TEAEs) [53]. Eight studies reported simi-
lar outcomes between groups, but failed to provide a for-
mal statistical analysis of between-group comparisons
[55, 56, 69, 70, 75, 98, 102–104].
Most studies reported similar safety profiles between
groups. An exception was the PLANETAS extension study
of infliximab in patients with ankylosing spondylitis, in
which TEAEs were considerably more frequent in the
switched group [71% (60 patients out of 84) vs 49% (44
patients out of 90) in the group remaining on originator
biologic] and included TEAEs that were considered related
to the study drug [39% (33 patients out of 84) vs 22% (20
patients out of 90)] [61].
3.2 Non-medical Switching: Real-world Efficacy
and Safety Data
All of the 27 observational, non-medical switching studies
reported data on main efficacy parameters after switching
compared with baseline/before switching (Table 2)
[43–52, 54, 58, 62, 63, 65–68, 71, 72, 77, 79, 83, 87–90,
105]. The originator biologics/biosimilars assessed were
infliximab (20 studies [43–52, 54, 58, 62, 63,
65–68, 71, 72]), ESAs (two studies [77, 79]), insulin (two
studies [83, 87]) and growth hormone (three studies
[88–90]).
Of 16 studies that reported statistical analyses, 13 found
no statistically significant differences for main efficacy
parameters [43, 46–49, 58, 62, 67, 68, 71, 77, 79, 87],
although six of these observed changes for some parame-
ters (in favour of the pre-switch and post-switch treatments
in five studies and one study, respectively). There was a
need for additional medication to control increased disease









































































































































































































































































































































































































































































































































































































































































































































































Review of Biosimilarity and Interchangeability of Biologics 43
infliximab in four of 83 patients with inflammatory bowel
disease (IBD) [68] and in 13 of 28 patients undergoing
chemotherapy and switching epoetins [77]; a significant
increase in median C-reactive protein values (from 1.95 to
4.0 mg/L; P\0.05) and median pain scores (from 28.8 to
38.1 mm on a scale of 0–100; P\0.05) in patients with
IBD switching from originator to biosimilar infliximab
[43]; a significant increase in disease activity (mean Bath
Ankylosing Spondylitis Activity Index, from 3.8 to 4.3;
P\0.05) in patients with spondyloarthritis after switching
to biosimilar infliximab [71]; a small, significant increase
in total daily insulin dose (from 0.62 to 0.65 U/kg/day;
P\0.05) in patients with type 1 or type 2 diabetes mellitus
switched to a biosimilar insulin [87]; but a significant
decrease (i.e. improvement) in duration of morning stiff-
ness [median duration, from 7.2 to 5.8 (no units provided);
P = 0.02] in patients with arthritis switching from origi-
nator to biosimilar infliximab [47]. In the three remaining
studies that included statistical analyses, IBD disease
activity significantly improved in paediatric patients swit-
ched from originator to biosimilar infliximab (P\0.05;
actual values not reported) [66], but significantly worsened
in adults who underwent a similar switch (median IBD-
Control-8 score, from 11 to 14; P\0.05) [63], and primary
failure was significantly lower in patients with IBD swit-
ched from originator to biosimilar infliximab than in
patients switched from other biologics or who were treat-
ment naı̈ve (0 vs 11 and 10%, respectively; P\0.05) [50].
Eight studies reported that switching generally had no
noticeable effect, but did not provide a formal statistical
analysis of between-group comparisons or based this con-
clusion on modelling [44, 45, 52, 65, 83, 88–90]. Two
studies reported on switching from infliximab originator to
biosimilar. In one, relapse was reported in seven of 23
patients with rheumatic diseases within about 2 months
after switching [51], and in the other, three of 36 patients
with IBD discontinued within 1 year of switching because
of loss of efficacy [54].
In terms of safety data after switching, eight studies
reported no concerns or similar safety profiles before and
after switching [43, 44, 47, 50, 62, 63, 79, 87, 89], six
studies reported no general safety data
[45, 51, 72, 77, 83, 90], and 12 studies reported adverse
events such as injection site pain, acute hypersensitivity
reactions, rash and infusion reactions after switching
(although most did not provide comparative data from
before switching) [46, 48, 49, 52, 54, 58, 65–68, 71, 88].
3.3 Switching, Reasons Not Reported: Efficacy
and Safety Data
All seven observational studies that did not include reasons
for switching assessed efficacy parameters after switching
compared with baseline/before switching (Table 3)
[57, 59, 64, 76, 78, 80, 100]. Three involved infliximab
[57, 59, 64], three ESAs [76, 78, 80] and one rituximab
[100].
Two studies included statistical analyses, both of which
found no significant differences for main efficacy param-
eters [57, 78]. In one of these studies, on ESAs in patients
on haemodialysis, switching to a biosimilar resulted in
higher mean drug dose requirements (from 8765 to
10,886 IU/week; P\0.05) to maintain haemoglobin levels
[78]. Of the five studies not reporting a formal statistical
analysis of between-group comparisons, four reported that
switching had no noticeable effect [64, 76, 80, 100] and
one reported disease worsening in five of 46 evaluable
patients with IBD (11%) during 30 weeks of follow-up
after switching from infliximab originator to biosimilar
[59].
In terms of safety data after switching, one study
reported similar patterns to before switching [57], one (in
patients with IBD) reported three cases of infusion reaction
and one of pneumonia in the switch group, which com-
prised 60 patients (vs none in the treatment-naive group,
which comprised 113 patients) [59], one reported adverse
events (cutaneous leishmaniasis) only when these were a
reason for treatment discontinuation [64], and four studies
did not report safety data [76, 78, 80, 100].
3.4 Switching: Immunogenicity Data
The relative frequency of ADAs in biologic originator and
biosimilars was reported in 27 studies, of which 18 were
clinical studies [53, 55, 56, 60, 61, 69, 70,
73, 81, 82, 84–86, 91, 92, 95–99, 101–104] and nine were
observational [46–48, 52, 57, 63, 67, 68, 71, 105]. In
26 studies (17 clinical: follow-up 12–52 weeks
[53, 55, 56, 60, 61, 69, 70, 73, 81, 82, 84, 85, 91, 92, 95–
99, 101–103]; nine observational: follow-up 6–13 months
[46–48, 52, 57, 63, 67, 68, 71, 105]), there were either no
cases of ADAs, or the incidence of ADAs was similar in
both groups.
A significantly higher proportion of patients with ADAs
in the switched group than the non-switched group (19% vs
8% overall; P = 0.01) was reported in a clinical study of
insulin in type 2 diabetes mellitus (ELEMENT 2) during
24 weeks of follow-up [84–86].
Comparative data regarding neutralising ADAs were
reported in six studies (all clinical); none of which
observed any clinically relevant [60, 96, 97, 104] or sig-
nificant [61, 73, 96] differences between groups. No studies
reported any treatment failure related to the development of
ADAs.
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4 Discussion
4.1 Clinical Considerations
This systematic literature review reveals important evi-
dence gaps around the safety of switching between origi-
nator biologics and biosimilars or between biosimilars.
There is a paucity of data from large studies of sufficient
statistical power for efficacy, safety and immunogenicity
risk considerations. There is little information on
immunogenicity outside of clinical studies, with only nine
of 34 included observational studies (26%) reporting such
data. There is a general lack of robustness of evidence and
no long-term data, with only eight of the included studies
having a post-switch follow-up period beyond 1 year. This
is important because patients may be exposed to treatment
long-term and, although safety issues such as ADAs occur
most commonly early on during treatment with biologics
[106], they have been reported to arise only after the first
year of treatment in some patients [107, 108]: a meta-
analysis of 68 studies on incidence of ADAs to TNF
inhibitors found that these first developed as early as
2 weeks, but also as late as 3 years, after treatment initia-
tion [108]. There is large heterogeneity in the design of
available studies including the number of switches and
permutations of switch scenarios, use of formal equiva-
lence or non-inferiority margins, and assessment of safety
and immunogenicity risk, making it difficult to draw con-
clusions from the data.
Demonstration of interchangeability is a complex pro-
cess that requires clinical studies in addition to those
conducted to establish biosimilarity [109]. In the absence
of specifically designed cross-over or multiple switch
studies, demonstration of biosimilarity is not adequate to
establish interchangeability [109]. The study duration
needs to be clinically informed and will not be the same in
every setting. Long-term studies are needed if treatment is
chronic. A particular challenge when designing inter-
changeability studies is how to define the non-inferiority or
equivalence margin, a topic that is covered by the recent
FDA draft guidance [19]. In most studies in the current
review, analyses around interchangeability were fairly
limited, for example, taking a lack of a statistically sig-
nificant difference as a lack of need for concern even when
confidence intervals were wide [60]. Only five studies
specified a formal equivalence or non-inferiority margin
[53, 74, 81, 82, 95]. Formal, standardised definitions
around margins are needed.
To demonstrate interchangeability, a study needs to
show that even multiple switches between products
deemed biosimilar do not affect patient safety or treatment
effectiveness. The FDA draft guidance on
interchangeability states that the switching arm should
incorporate at least two separate exposure periods to each
of the two products (i.e. at least three switches, with each
switch crossing over to the alternate product) [19]. The
EGALITY (etanercept) and NOR-SWITCH (infliximab)
trials focused specifically on the impact of switching
between these TNF-a originator biologics and their corre-
sponding biosimilars, but NOR-SWITCH was not designed
to assess the effects of multiple switches [53, 103]. In the
EGALITY study, patients with chronic plaque psoriasis
either continued with their original therapy or underwent
three treatment switches at 6-weekly intervals [103].
TEAEs were shown to be similar between groups, ADAs
were low titre and transient, and no neutralising antibodies
were detected. Although the study follow-up period was
short and numbers small (200 switched patients), the study
is an important addition to the evidence.
In NOR-SWITCH, 240 patients were switched across
six diseases, with numbers per disease indication ranging
from 16 patients for psoriatic arthritis to 77 patients for
Crohn’s disease. Disease worsening, the primary endpoint
in NOR-SWITCH, was defined differently across the six
diseases, with the data then pooled across indications for
analysis. The study showed similar results for switched and
non-switched groups for disease worsening and safety
although, as the authors of the study commented, it was not
powered to demonstrate non-inferiority within each diag-
nostic group, and thus the pooled analysis used does not
allow conclusions about individual diseases [53, 110].
Both EGALITY and NOR-SWITCH were relatively
small, short-duration studies, and larger studies with
longer-term follow-up are still needed, in particular for
patients with rheumatic diseases and IBD who are exposed
to treatments over many years. In general, once inter-
changeability is deemed to be established, the relevant
information will need to be passed on to healthcare pro-
viders to allow them to make individualised treatment
decisions for their patients.
Differences exist regarding the regulatory approval
pathways for biosimilars in different parts of the world.
The regulatory framework around biosimilars is robust in
the highly regulated markets of Europe, the USA, Canada,
Australia and Japan, with South Korea also having posi-
tioned itself as a high-quality global biosimilars leader,
while in emerging markets in south-east Asia, Latin
America and Africa the regulatory pathways for biosimi-
lars are still evolving [111]. These differences need to be
taken into account when interpreting results from switching
studies. Almost all of the studies identified for inclusion in
the current review originated from highly regulated mar-
kets, with the exception of seven studies that included
emerging markets [75, 83, 87, 93, 94, 99, 100], of which
six reported similar outcomes for switched and non-
Review of Biosimilarity and Interchangeability of Biologics 45
switched groups and one, from South Africa, reported a
requirement for increased insulin dose post-switch [87].
While not the focus of the current review, changing
from one originator biologic to another is relatively com-
mon in clinical practice, most likely because of inefficacy
or intolerability issues with the initial treatment [112, 113].
It is important to note, however, that this scenario is very
different from switching between an originator biologic
and its biosimilar or between different biosimilars of the
same biologic: for example, two originator biologics tar-
geting a given molecule may bind different epitopes,
whereas a biologic and its biosimilar or two biosimilars of
the same biologic should bind the same epitope. This dif-
ference probably explains why ADAs to infliximab
demonstrate identical reactivity towards its biosimilar,
whereas ADAs to adalimumab do not cross-react with
infliximab or its biosimilar [114].
4.2 Glycosylation Patterns
Originator biologics and their biosimilars are often glyco-
proteins, which may be inherently immunogenic, whereas
small molecules and their generics are only sometimes
immunogenic, usually due to haptenating endogenous
proteins [115]. There are no well-designed investigations
into the clinical implications of glycosylation differences
that may occur in production of biosimilars [41, 116]. The
terminal sugars of glycans attached to immunoglobulin
heavy chain have been shown to be critical for safety and/
or efficacy of therapeutic monoclonal antibodies. For
example, removal of fucose residues from these glycans
can result in up to a 100-fold increase in affinity of anti-
bodies to natural killer cells, which mediate antibody-de-
pendent cellular cytotoxicity [117, 118]. In addition, a high
degree of galactosylation has been shown to promote
activation of complement in vitro [119]. Different patterns
of glycosylation have been shown to influence the phar-
macodynamic and pharmacokinetic behaviour of biologics,
sometimes resulting in a reduction of the serum half-life of
therapeutic antibodies [120]. Such changes have been used
purposely as part of the product development process, such
as when two extra glycosylation sites were engineered into
recombinant human erythropoietin (EPO), resulting in a
new, stand-alone product—darbepoetin alfa, with a three-
fold longer half-life—that could be administered less fre-
quently [121]. A recent study has also demonstrated that
the biological activity of EPO glycoforms varies depending
on the glycosylation site occupancy pattern [122].
At present, no clinical studies have shown adverse
effects of immunogenicity associated with therapeutics
with high levels of non-glycosylated heavy chains; how-
ever, Fc glycan structural elements may be involved in
adverse immune reactions. A high prevalence of
hypersensitivity reactions to cetuximab, a monoclonal
antibody approved for use in colorectal cancer and squa-
mous-cell carcinoma of the head and neck, has been
reported [123]. NeuGc, a non-human sialic acid that is
found on some therapeutic proteins, can reduce efficacy
due to rapid clearance of the biotherapeutic, and has been
reported to cause hypersensitivity. In summary, production
processes can change the glycosylation profiles of product
biosimilars [41], which may potentially affect safety and
efficacy. To date, the clinical implications of these changes
are not well understood.
4.3 Immunogenicity Risk
If glycoproteins are sufficiently different from endogenous
analogues, then patients may not exhibit immunological
tolerance to them, thus rendering such glycoproteins
immunogenic. In addition, variations can occur as a result
of insertion of xenogeneic amino acid sequences when
biologics are made in xenogeneic cells, which can enhance
their immunogenicity [124, 125]. Even when fully
humanised and glycosylated, therapeutic monoclonal anti-
bodies can be immunogenic because they form immune
complexes with target proteins, undergo phagocytosis and
potentially activate inflammation [126]. Even within the
human population, genes encoding the constant domains of
immunoglobulins are highly polymorphic (known as allo-
types), and each therapeutic is made from only one variant,
which, therefore, may be recognised as non-self in indi-
viduals who lack that polymorphism [40, 41, 127–129].
Therefore, tolerance to an originator biologic does not
necessarily predict immunological tolerance to its biosim-
ilar and vice versa.
Significant effects of ADAs can be divided into those
that neutralise the therapeutic action of the drug and/or its
endogenous analogue and those that mediate hypersensi-
tivity reactions to the drug. For example, EPO-induced
ADA that neutralises endogenous EPO has been implicated
in rare cases of pure red cell aplasia [130]. Unsurprisingly,
there is also some evidence that ADAs arising against the
reference product can also react to its biosimilars [114].
For example, in a retrospective analysis of 250 patients
with arthritis who received either a reference biologic
(infliximab) or a biosimilar, none of whom had undergone
switching, ADAs against infliximab (detected in 126
patients) cross-reacted in in vitro antibody assays with
either of two biosimilar products [114]. In the current
review, no studies reported any treatment failure related to
the development of ADAs. Comparative data on neutral-
ising drug antibodies were reported in only three studies.
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4.4 Regulatory Considerations
Ongoing post-marketing pharmacovigilance and accurate
documentation of the specific product used by each patient
are important. The current lack of standardisation of
naming conventions for biosimilars poses several potential
concerns. A unique name for the reference product and its
biosimilar supports traceability in relation to pharma-
covigilance and adverse event reporting [11, 131, 132].
Prescribers need to be able to distinguish between the
reference product and its biosimilar to avoid prescribing
errors. Naming conventions vary across regions, with the
EU licensing biosimilars under the same international non-
proprietary name (INN) as the originator and the FDA
using a non-specific four-letter suffix (suggested by the
sponsor) added to the non-proprietary name. The Aus-
tralian TGA currently uses the locally approved name
without any unique identifier for a biologic and its
biosimilar, but is considering various options [11]; hence,
at present, traceability may be difficult when multiple
switches occur. A study on the traceability of biopharma-
ceuticals in spontaneous reporting systems over the period
2004–2010 found that, of six biosimilars approved in
Europe at the time (sold under 12 different trade names),
five contained the same INN as the innovator [133]. The
product name was clearly identifiable for 90–96% of bio-
pharmaceuticals for which biosimilars were available in the
EU, although batch traceability was poorly maintained
[133]. Given the evidence gaps and the difficulty of con-
ducting randomised trials, particularly in the post-market-
ing setting, there is a need to establish or use pre-existing
registries and administrative data, and to develop novel
approaches to understanding the effectiveness data being
generated by what are, in effect, natural, real-world
experiments.
5 Conclusions
In summary, results from this systematic literature review
show important evidence gaps around the safety of
switching between originator biologics and biosimilars or
between biosimilars. While emergent evidence from the
EGALITY and NOR-SWITCH studies suggests that
switching between TNF-a biologics and their correspond-
ing biosimilars can be safe and efficacy is not compro-
mised, we believe that sufficiently powered and
appropriately statistically analysed clinical trials and
pharmacovigilance studies, with long-term follow-ups and
multiple switching sequences, are needed to support deci-
sion-making around biosimilar interchangeability. In the
interim, switching should remain a clinical decision made
by the treating physician and the patient based on available
evidence and individual patient circumstances. Global
harmonisation of the regulatory approach to these agents
would facilitate an improved understanding of the safety
and efficacy of biosimilars.
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R, Di Turi R. Switch to biosimilars in hemodialysis patients:
efficacy, safety and cost analysis in a single centre. Ricerca e
Pratica. 2017;33(1):5–12.
80. Ohta S, Yasuno N, Inomoto Y, Matsuda K, Nakagawa Y,
Sasagawa I, et al. Efficacy of once or twice weekly adminis-
tration of epoetin kappa in patients receiving hemodialysis: a
retrospective study. Exp Ther Med. 2014;7(1):27–30.
81. Wiecek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin
alfa and epoetin zeta in patients with renal anemia on dialysis:
posthoc analysis. Adv Ther. 2010;27(12):941–52.
82. Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev
R. Comparison of the therapeutic effects of epoetin zeta to
epoetin alfa in the maintenance phase of renal anaemia treat-
ment. Curr Med Res Opin. 2008;24(3):625–37.
83. Balili CAV, Mendoza ESR, Mercado-Asis LB. Shifting to
biosimilar insulin preparation: impact on glycemic control and
cost. Endocrine Reviews. 2015;36:abstract THR-659.
84. Hadjiyianni I, Dahl D, Lacaya LB, Pollom RK, Chang CL, Ilag
LL. Efficacy and safety of LY2963016 insulin glargine in
patients with type 1 and type 2 diabetes previously treated with
insulin glargine. Diabetes Obes Metab. 2016;18(4):425–9.
85. Ilag LL, Deeg MA, Costigan T, Hollander P, Blevins TC,
Edelman SV, et al. Evaluation of immunogenicity of
LY2963016 insulin glargine compared with Lantus(R) insulin
glargine in patients with type 1 or type 2 diabetes mellitus.
Diabetes Obes Metab. 2016;18(2):159–68.
86. Rosenstock J, Hollander P, Bhargava A, Ilag LL, Pollom RK,
Zielonka JS, et al. Similar efficacy and safety of LY2963016
insulin glargine and insulin glargine (Lantus(R)) in patients with
type 2 diabetes who were insulin-naive or previously treated
with insulin glargine: a randomized, double-blind controlled
trial (the ELEMENT 2 study). Diabetes Obes Metab.
2015;17(8):734–41.
87. Segal D, Tupy D, Distiller L. The Biosulin equivalence in
standard therapy (BEST) study—a multicentre, open-label, non-
randomised, interventional, observational study in subjects using
Biosulin 30/70 for the treatment of insulin-dependent type 1 and
type 2 diabetes mellitus. S Afr Med J. 2013;103(7):458–60.
88. Flodmark CE, Lilja K, Woehling H, Jarvholm K. Switching
from originator to biosimilar human growth hormone using
dialogue teamwork: single-center experience from Sweden. Biol
Ther. 2013;3:35–43.
89. Gila AG, Garcia MP. Switching from the original to the
biosimilar recombinant human GH-Omnitrope: an experience
of a single paediatric centre in Spain. Horm Res Paediatr.
2014;82:414 (abstract).
90. Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz
F, et al. Switching to Omnitrope from other recombinant
human growth hormone therapies: a retrospective study in an
integrated healthcare system. Biol Ther. 2014;4(1–2):27–39.
91. Belleli R, Fisch R, Renard D, Woehling H, Gsteiger S.
Assessing switchability for biosimilar products: modelling
approaches applied to children’s growth. Pharm Stat.
2015;14(4):341–9.
92. Romer T, Zabransky M, Walczak M, Szalecki M, Balser S.
Effect of switching recombinant human growth hormone:
comparative analysis of phase 3 clinical data. Biol Ther.
2011;1:5.
50 R. A. McKinnon et al.
93. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A.
XM02, the first granulocyte colony-stimulating factor biosimi-
lar, is safe and effective in reducing the duration of severe
neutropenia and incidence of febrile neutropenia in patients with
non-Hodgkin lymphoma receiving chemotherapy. Leuk Lym-
phoma. 2009;50(3):374–9.
94. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau
H, Del Giglio A. XM02, the first biosimilar G-CSF, is safe and
effective in reducing the duration of severe neutropenia and
incidence of febrile neutropenia in patients with small cell or
non-small cell lung cancer receiving platinum-based
chemotherapy. J Thorac Oncol. 2009;4(6):736–40.
95. Krendyukov A, Harbeck N, Gascon P, Gattu S, Li Y, Blackwell
KL. Safety and efficacy of alternating treatment with EP2006, a
filgrastim biosimilar, and reference filgrastim for the prevention
of severe neutropenia, in patients with breast cancer receiving
myelosuppressive chemotherapy. J Clin Oncol. 2017;35:ab-
str10116 (abstract).
96. Gooderham M, Spelman L, Kaliaperumal A, Costanzo A, Nar-
butt J, Zhang N, et al. Single transition from adalimumab to
ABP 501: evaluation of immunogenicity in a phase 3 study in
subjects with moderate to severe plaque psoriasis. J Am Acad
Dermatol. 2016;74(5):AB275 (abstract).
97. Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur
P, et al. Clinical similarity of biosimilar ABP 501 to adali-
mumab in the treatment of patients with moderate to severe
plaque psoriasis: a randomized, double-blind, multicenter, phase
III study. J Am Acad Dermatol. 2017;76(6):1093–102.
98. Weinblatt M, Baranauskaite A, Niebrzydowski J, Dokoupilova
E, Zielinska A, Sitek-Ziolkowska K, et al. Sustained efficacy
and comparable safety and immunogenicity after transition to
SB5 (an adalimumab biosimilar) vs continuation of the adali-
mumab reference product in patients with rheumatoid arthritis:
results of phase III study EUCLAR 2016; 8–11 June 2016;
London UK (abstract FRI0161). Arthritis Rheumatol.
2016;68(suppl 10):abstract 604.
99. Nasonov E, Mazurov V, Plaksina T, Nesmeyanova O, Knyazeva
L, Eremeeva A, et al. Interchangeability of innovator rituximab
and its biosimilar: results from international controlled com-
parative 1-year study in patients with active rheumatoid arthritis.
Arthritis Rheumatol. 2016;68:2046–7.
100. Roy PS, John S, Karankal S, Kannan S, Pawaskar P, Gawande J,
et al. Comparison of the efficacy and safety of rituximab
(Mabthera) and its biosimilar (Reditux) in diffuse large B-cell
lymphoma patients treated with chemo-immunotherapy: a ret-
rospective analysis. Indian J Med Paediatr Oncol.
2013;34(4):292–8.
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